Centiva Capital’s Dr. Reddy's Laboratories RDY Stock Holding History

Centiva Capital’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-22,335	Closed	-$340K	–	2521
2024 Q2	$340K	Buy	+22,335	New	+$320K	0.01%	1400

Other funds holding RDY

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Centiva Capital's RDY Position: Q3 2024 in Review

Centiva Capital sold out of Dr. Reddy's Laboratories (RDY) in Q3 2024, closing a stake of 22,335 shares — an estimated $340K sold.

Centiva Capital first reported a position in RDY in Q2 2024 and held it in 1 quarter. The position peaked at $340K in Q2 2024. 228 funds tracked by Wall St. Rank hold RDY as of Q3 2024.

Centiva Capital reported no remaining Dr. Reddy's Laboratories position as of Q3 2024 after selling out during the quarter.
Centiva Capital sold 22,335 Dr. Reddy's Laboratories shares in Q3 2024, an estimated $340K.
Centiva Capital first reported a position in Dr. Reddy's Laboratories in Q2 2024 and held it in 1 quarter.
Centiva Capital's Dr. Reddy's Laboratories position peaked at $340K in Q2 2024.
228 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.